

NATCO PHARMA ASIA PTE. LTD.
(Incorporated in Singapore)
Reg. No: 201230076Z

**ANNUAL FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR
ENDED 31 MARCH 2021**

<u>CONTENTS</u>	<u>PAGE</u>
DIRECTORS' STATEMENT	1 - 2
INDEPENDENT AUDITOR'S REPORT	3 - 5
STATEMENT OF FINANCIAL POSITION	6
STATEMENT OF COMPREHENSIVE INCOME	7
STATEMENT OF CHANGES IN EQUITY	8
STATEMENT OF CASH FLOWS	9
NOTES TO THE FINANCIAL STATEMENTS	10 - 39

DIRECTORS' STATEMENT FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021

The directors present their statement to the members together with the audited financial statements of Natco Pharma Asia Pte. Ltd. (the "Company") for the financial year ended 31 March 2021.

1. OPINION OF THE DIRECTORS

In the opinion of the directors,

- (a) the financial statements of the Company are drawn up so as to give a true and fair view of the financial position of the Company as at 31 March 2021 and the financial performance, changes in equity and cash flows of the Company for the year then ended; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

2. DIRECTORS

The directors of the Company in office at the date of this statement are:

Mente Subba Rao
Virkar Girish Suresh
Prabhakaran Mangayarkarasi

3. ARRANGEMENTS TO ENABLE DIRECTORS TO ACQUIRE SHARES OR DEBENTURES

Neither at the end of nor at any time during the financial year was the Company a party to any arrangement whose object is to enable the directors of the Company to acquire benefits by means of the acquisition of shares or debentures of the Company or any other body corporate.

4. DIRECTORS' INTEREST IN SHARES OR DEBENTURES

According to the register of directors' shareholdings kept by the Company under section 164 of the Singapore Companies Act, Chapter 50 (the "Act"), the directors of the Company who held office at the end of the financial year had no interests in the shares or debentures of the Company and its related corporations except as stated below:

<u>Name of directors</u>	<u>Direct interest</u>	
	<u>At beginning of the financial year</u>	<u>At end of the financial year</u>
<u>Ordinary shares of the Holding Company</u>		
Mente Subba Rao	44,850	44,850
<u>Ordinary shares of the Company</u>		
Virkar Girish Suresh	5,000	5,000

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

DIRECTORS' STATEMENT FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021

5. SHARE OPTIONS

There were no share options granted during the financial year to subscribe for unissued shares of the Company.


There were no shares issued during the financial year by virtue of the exercise of options to take up unissued shares of the Company.

There were no unissued shares of the Company under option as at the end of the financial year.

6. AUDITORS

V. P. Kumaran & Co. has expressed its willingness to accept re-appointment as auditor.

On behalf of the Board of Directors


.....
Virkar Girish Suresh
Director


.....
Prabhakaran Mangayarkarasi
Director

Singapore,

28 APR 2021

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
NATCO PHARMA ASIA PTE. LTD.****Report on the Audit of the Financial Statements****Opinion**

We have audited the financial statements of Natco Pharma Asia Pte. Ltd. (the "Company"), which comprise the statement of financial position as at 31 March 2021, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements are properly drawn up in accordance with the provisions of the Companies Act, Chapter 50 (the "Act") and Financial Reporting Standards in Singapore (FRSs) so as to give a true and fair view of the financial position of the Company as at 31 March 2021 and of the financial performance, changes in equity and cash flows of the Company for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with Singapore Standards on Auditing (SSAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority (ACRA) Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. The other information comprises the Directors' Statement as set out on pages 1 and 2.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Directors for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and FRSSs, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as going concern. If we conclude that a material uncertainty exist, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.

VP Kumaran & Co

V. P. KUMARAN & CO
Public Accountants and
Chartered Accountants

Singapore,
28 April 2021

AJ/SM/KV

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2021

	Note	2021	2020
		\$	\$
ASSETS			
Non-current assets			
Property, plant and equipment	4	41,360	19,529
Current assets			
Inventories	5	359,021	109,421
Cash	6	227,779	57,882
Trade and other receivables	7	3,062,914	2,437,389
Total current assets		3,649,714	2,604,692
Total assets		3,691,074	2,624,221
LIABILITIES			
Current liabilities			
Trade and other payables	8	485,921	312,613
Interest bearing loans	9	2,140,163	2,113,325
Total current liabilities		2,626,084	2,425,938
Net assets		1,064,990	198,283
EQUITY			
Share capital	10	2,100,000	2,100,000
Accumulated losses		(1,035,010)	(1,901,717)
Total equity		1,064,990	198,283

The accompanying notes form an integral part of these financial statements.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021

	Note	2021	2020
		\$	\$
CONTINUING OPERATIONS			
REVENUE			
Sale of goods		1,889,454	500,272
Other income	11	124,063	104,778
		<u>2,013,517</u>	<u>605,050</u>
COSTS AND EXPENSES			
Change in inventories		(249,600)	(31,518)
Purchase		857,100	267,446
Depreciation	4	34,836	34,320
Finance cost	12	108,320	108,333
Staff cost	13	257,231	301,887
Other operating expenses		138,923	177,224
Total costs and expenses		<u>1,146,810</u>	<u>857,692</u>
PROFIT/(LOSS) BEFORE TAX	14	866,707	(252,642)
INCOME TAX EXPENSE	15	-	-
PROFIT/(LOSS) REPRESENTING TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE FINANCIAL YEAR		<u>866,707</u>	<u>(252,642)</u>

The accompanying notes form an integral part of these financial statements.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021

	Share capital	Accumulated losses	Total equity
	\$	\$	\$
2021			
Balance at beginning of financial year	2,100,000	(1,901,717)	198,283
Total comprehensive income for the financial year	-	866,707	866,707
Balance at end of financial year	<u>2,100,000</u>	<u>(1,035,010)</u>	<u>1,064,990</u>
2020			
Balance at beginning of financial year	1,850,000	(1,649,075)	200,925
Shares issued during the financial year (Note 10)	250,000	-	250,000
Total comprehensive loss for the financial year	-	(252,642)	(252,642)
Balance at end of financial year	<u>2,100,000</u>	<u>(1,901,717)</u>	<u>198,283</u>

The accompanying notes form an integral part of these financial statements.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021

	Note	2021 \$	2020 \$
Cash flows from operating activities			
Profit/(Loss) before tax		866,707	(252,642)
Adjustment for:			
Depreciation of property, plant and equipment	4	4,695	3,161
Depreciation of right use of asset	4	30,141	31,159
Interest expense		108,320	108,333
Interest income		(103,372)	(102,523)
Operating profit/(loss) before working capital changes		<u>906,491</u>	<u>(212,512)</u>
Changes in working capital:			
Inventories		(249,600)	(31,519)
Trade and other receivables		(625,525)	(216,771)
Trade and other payables		173,308	229,138
Cash generated from/(used in) operations		<u>204,674</u>	<u>(231,664)</u>
Interest expense		(108,320)	(108,333)
Interest income		103,372	102,523
Net cash flows generate from/(used in) operating activities		<u>199,726</u>	<u>(237,474)</u>
Capital cash flows from investing activities			
Purchase of property, plant and equipment	4	-	(326)
Net cash flows used in investing activities		<u>-</u>	<u>(326)</u>
Capital cash flows from financing activities			
Proceeds from issuance of ordinary shares	10	-	250,000
Proceeds from loan		-	18,728
Repayment of principal portion of lease liability		(29,829)	(13,325)
Repayment of int-bearing loans and borrowings		-	(39,659)
Net cash flows (used in)/generated from financing activities		<u>(29,829)</u>	<u>215,744</u>
Net change in cash and cash equivalents		169,897	(22,056)
Cash and cash equivalents at beginning of financial year		<u>57,882</u>	<u>79,938</u>
Cash and cash equivalents at end of financial year	6	<u>227,779</u>	<u>57,882</u>

The accompanying notes form an integral part of these financial statements.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

These notes form an integral part of the financial statements.

1. CORPORATE INFORMATION

Natco Pharma Asia Pte. Ltd. (the “Company”) is a limited private liability company incorporated and domiciled in Singapore.

The registered office of the Company is located at

111 North Bridge Road
#23-05 Peninsula Plaza
Singapore 179098

The principal place of business of Company is at

62 Ubi Road 1,
#03-21, Oxley Bizhub 2,
Singapore 408734

The principal activities of the Company are those relating to wholesale of medical and pharmaceutical products (western) and R & D pharmaceutical products.

The holding company during the financial year is Natco Pharma Limited incorporated in India.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

The financial statements of the Company have been prepared in accordance with Singapore Financial Reporting Standards (FRS). The financial statements have been prepared on the historical cost basis except as disclosed in the accounting policies below. The financial statements are presented in Singapore dollar (SGD or \$) and all values are rounded to the nearest dollar as indicated.

2.2 Adoption of new and amended standards and interpretations

The accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Company has adopted all the new and amended standards which are relevant to the Company and are effective for annual financial periods beginning on or after 1 April 2020. The adoption of these standards did not have any material effect on the financial performance or position of the company.

NOTES TO THE FINANCIAL STATEMENTS - 31 MARCH 2021

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.3 Standards issued but not yet effective (continued)

The Company has not adopted the following standards that have been issued but not yet effective:

Description	Effective for annual periods beginning on or after
Amendments to FRS 116 <i>Leases: Covid-19 - Related Rent Concessions</i>	1 June 2020
Amendments to FRS 109 <i>Financial Instruments</i> , FRS 39 <i>Financial Instruments: Recognition and Measurement</i> , FRS 107 <i>Financial Instruments: Disclosures</i> , FRS104 <i>Insurance Contracts</i> , FRS 116 <i>Leases: Interest Rate Benchmark Reform - Phase 2</i>	1 January 2022
Amendments to FRS 16 <i>Property, Plant and Equipment</i> Proceeds before Intended Use	1 January 2022
Amendments to FRS 37 <i>Provisions, Contingent Liabilities and Contingent Assets: Onerous Contracts - Cost of Fulfilling a Contract</i>	1 January 2022
Annual improvements to FRSs 2018-2020	1 January 2022
Amendments to FRS 1 <i>Presentation of Financial Statements: Classification of Liabilities as Current or Non-current</i>	1 January 2023

The directors expect that the adoption of the standards above will have no material impact on the financial statements in the year of initial application.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.4 Foreign currency

The Company's financial statements are presented in Singapore dollar, which is also the Company's functional currency.

Transactions and balances

Transactions in foreign currencies are measured in the functional currency of the Company and are recorded on initial recognition in the functional currency at exchange rates approximating those ruling at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the end of the reporting period. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.

Exchange differences arising on the settlement of monetary items or on translating monetary items at the end of the reporting period are recognised in statement of comprehensive income.

2.5 Property, property, plant and equipment

All items of property, property, plant and equipment are initially recorded at cost. Subsequent to recognition, property, property, plant and equipment other than freehold land and buildings are measured at cost less accumulated depreciation and any accumulated impairment losses. The cost includes the cost of replacing part of the property, property, plant and equipment and borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying property, property, plant and equipment. The cost of an item of property, plant and equipment is recognised as an asset if, and only if, it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

When significant parts of property, plant and equipment are required to be replaced in intervals, the Company recognises such parts as individual assets with specific useful lives and depreciation, respectively. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the property, plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in statement of comprehensive income as incurred.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.5 Property, property, plant and equipment (Continued)

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

- | | |
|--------------------------|-------------------|
| • Office equipment | 3 years |
| • Furniture and fittings | 3 years |
| • Renovations | 3 years |
| • Leasehold building | Over lease period |

The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

The residual value, useful life and depreciation method are reviewed at each financial year-end, and adjusted prospectively, if appropriate.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of the asset is included in statement of comprehensive income in the year the asset is derecognised.

2.6 Cash and cash equivalents

Cash and cash equivalents comprise of cash balances and bank deposits which are subject to an insignificant risk of change in value.

2.7 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is calculated using the first-in first-out method and comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

When necessary, allowance is provided for damaged, obsolete and slow moving items to adjust the carrying value of inventories to the lower of cost and net realisable value.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.8 Impairment of non-financial assets

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when an annual impairment testing for an asset is required, the Company makes an estimate of the asset's recoverable amount.

An asset's recoverable amount is the higher of an asset's or cash-generating unit's fair value less costs of disposal and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. Where the carrying amount of an asset or cash generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

Impairment losses are recognised in profit or loss.

A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If that is the case, the carrying amount of the asset is increased to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss have been recognised previously. Such reversal is recognised in profit or loss.

2.9 Financial assets

Initial recognition and measurement

Financial assets are recognised when, and only when the entity becomes party to the contractual provisions of the instruments.

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at FVPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Trade receivables are measured at the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant financing component at initial recognition.

Subsequent measurement

Investments in debts instruments

Subsequent measurement of debt instruments depends on the Company's business model for managing the assets and the contractual cash flow characteristics of the assets. The three measurement categories for classification of debt instruments are:

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.9 Financial assets (continued)

Subsequent measurement (continued)

Investments in debts instruments (continued)

(i) Amortised cost

Financial assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Financial assets are measured at amortised cost using the effective interest method, less impairment. Gains and losses are recognised in profit or loss when the assets are derecognized or impaired, and through amortised process.

(ii) Fair value through other comprehensive income (FVOCI)

Financial assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represents solely payments of principal and interest, are measurement at FVOCI. Financial assets at FVOCI are subsequently measured at fair value. Any gains or losses from changes in fair value of the financial assets are recognised other comprehensive income, except for impairment losses, foreign exchange gains and losses and interest calculated using the effective interest method are recognised in profit and loss. The cumulative gain or loss previously recognised in other comprehensive income is reclassified from equity to profit or loss as a reclassification adjustment when the financial assets is de-recognised.

(iii) Fair value through profit or loss

Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on a debt instruments that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in profit or loss in the period in which it arise.

The Company only has debt instruments at amortised cost.

De-recognition

A financial asset is de-recognised where the contractual right to receive cash flows from the asset has expired. On de-recognition of a financial asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or loss that had been recognised in other comprehensive income for debt instruments is recognised in profit or loss.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.10 Impairment of financial assets

The Company recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is recognised for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).

For trade receivables, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment which could affect debtors' ability to pay.

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

2.11 Financial liabilities

Initial recognition and measurement

Financial liabilities are recognised when, and only when, the Company becomes a party to the contractual provisions of the financial instrument. The Company determines the classification of its financial liabilities at initial recognition.

All financial liabilities are recognised initially at fair value plus in the case of financial liabilities not at fair value through profit or loss, directly attributable transaction costs.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.11 Financial liabilities (continued)

Subsequent measurement

After initial recognition, financial liabilities that are not carried at fair value through profit or loss are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the liabilities are derecognised, and through the amortisation process.

De-recognition

A financial liability is de-recognise when the obligation under the liability is discharged or cancelled or expires. On de-recognition, the difference between the carrying amounts and the consideration paid is recognised in profit or loss.

2.12 Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated reliably.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value of money is material, provisions are discounted using a current pre tax rate that reflects, where appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

2.13 Government grants

Government grants are recognised as a receivable when there is reasonable assurance that the grant will be received and all attached conditions will be complied with.

When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, the fair value is recognised as deferred income on the statement of financial position and is recognised as income in equal amounts over the expected useful life of the related asset

When loans or similar assistance are provided by governments or related institutions with an interest rate below the current applicable market rate, the effect of this favourable interest is regarded as additional government grant

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.14 Employee benefits

Defined contribution plans

The Branch participates in the national pension schemes as defined by the laws of the country in which it has operations. In particular, the Branch makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to defined contribution pension schemes are recognised as an expense in the period in which the related service is performed.

2.15 Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

(a) As lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities representing the obligations to make lease payments and right-of-use assets representing the right to use the underlying leased assets.

Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.15 Leases (continued)

Right-of-use assets (continued)

If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. The accounting policy for impairment is disclosed in Note 2.9

The Company's right-of-use assets are presented within property, property, plant and equipment (Note 4).

Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate.

Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

The Company's lease liabilities are included in interest-bearing loans and borrowings (Note 9).

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.15 Leases (continued)

Short-term leases and leases of low-value assets

The Company applies the short-term lease recognition exemption to its short-term leases of machinery (i.e. those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low value assets are recognised as expense on a straight-line basis over the lease term.

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date: whether fulfillment of the arrangement is dependent on the use of a specific asset or assets or the arrangement conveys a right to use the asset, even if that right is not explicitly specified in an arrangement.

As lessee

Operating lease payments are recognised as an expense in statement of comprehensive income on a straight-line basis over the lease term. The aggregate benefit of incentives provided by the lessor is recognised as a reduction of rental expense over the lease term on a straight-line basis.

2.16 Revenue

Revenue is measured based on the consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties.

Revenue is recognised when the Company satisfies a performance obligation by transferring a promised good or service to the customer, which is when the customer obtains control of the good or service. A performance obligation may be satisfied at a point in time or over time. The amount of revenue recognised is the amount allocated to the satisfied performance obligation.

2.17 Taxes

Current income tax

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the end of the reporting period.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.17 Taxes (continued)

Current income taxes are recognised in statement of comprehensive income except to the extent that the tax relates to items recognised outside statement of comprehensive income, either in other comprehensive income or directly in equity.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST except:

- Where the GST incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- Receivables and payables that are stated with the amount of GST included.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.

2.18 Share capital and share issuance expenses

Proceeds from issuance of ordinary shares are recognised as share capital in equity. Incremental costs directly attributable to the issuance of ordinary shares are deducted against share capital.

2.19 Related parties

A related party is defined as follows:

- (a) *A person or a close member of that person's family is related to the Company if that person:*
 - (i) Has control or joint control over the Company;
 - (ii) Has significant influence over the Company; or
 - (iii) Is a member of the key management personnel of the Company or of a parent of the Company.
- (b) *An entity is related to the Company if any of the following conditions applies:*
 - (i) The entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others).

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.19 Related parties (continued)

- (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
- (iii) Both entities are joint ventures of the same third party.
- (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity.
- (v) The entity is a post-employment benefit plan for the benefit of employees of either the Company or an entity related to the Company. If the Company is itself such a plan, the sponsoring employers are also related to the Company;
- (vi) The entity is controlled or jointly controlled by a person identified in (a);
- (vii) A person identified in (a) (i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).

3. SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES

Judgments made in applying accounting policies

The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the reporting date. However, uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability affected in the future.

In the process of applying the accounting policies, management has made the following judgments, apart from those involving estimations, which have the most significant effects on the amounts recognised in the financial statements:

Determination of functional currency

The Company measures foreign currency transactions in the functional currency of the Company. In determining the functional currency of the Company, judgment is required to determine the currency that mainly influences sales prices for goods and services and of the country whose competitive forces and regulations mainly determine the sales prices of the goods and services. The functional currency of the Company is determined based on management's assessment of the economic environment in which it operates and its process of determining sales prices.

3. SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES (CONTINUED)

Determination of lease term of contracts with extension options

The Company determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised.

The Company applies judgement in evaluating whether it is reasonably certain whether or not to exercise the option to extend the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise the extension. After the commencement date, the Company reassesses the lease term whether there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to extend (e.g. construction of significant leasehold improvements or significant customisation to the leased asset). The extension options for leases of building are not included as part of the lease term because the Company typically leases building for not more than two years and, hence, will not exercise the extension options.

As at 31 March 2021, potential future (undiscounted) cash outflows of approximately \$41,600 (2020:\$13,500) have not been included in lease liabilities because it is not reasonably certain that the leases will be extended.

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period are discussed below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

Income taxes

The Company has exposure to income taxes. A degree of judgement is involved in determining the Company's provision for income taxes. There are certain transactions and computations for which the ultimate tax determination is uncertain during the ordinary course of business. The Company recognises liabilities for expected tax issues based on estimates of whether additional taxes would be due. Where the final tax outcome of these matters is different from the amounts that were initially recognised, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

Provision for expected credit losses of trade receivables

The Company uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns.

3. SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES (CONTINUED)

Key sources of estimation uncertainty (continued)

Provision for expected credit losses of trade receivables (continued)

The provision matrix is initially based on the Company's historical observed default rates. The Company will calibrate the matrix to adjust historical credit loss experience with forward-looking information. At every reporting date, historical default rates are updated and changes in the forward-looking estimates are analysed.

The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Company's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

Based on the estimated ECLs, the Company has concluded that the default rate is minimal and the ECLs is insignificant.

Leases – estimating the incremental borrowing rate

The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate to measure lease liabilities. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate therefore reflects what the Company 'would have to pay', which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.

The Company assesses whether there are any indicators of impairment for all non-financial assets at each reporting date.

When value in use calculations are undertaken, management estimates the expected future cash flows from the asset or the cash-generating unit and chooses a suitable discount rate in order to calculate the present value of those cash flows.

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

4. PROPERTY, PLANT AND EQUIPMENT

	Leasehold building	Office equipment	Furniture and fittings	Renovation	Total
2021	\$	\$	\$	\$	\$
Cost					
At beginning of financial year	44,142	16,521	7,003	64,685	132,351
Additions during the financial year	59,263	-	-	-	59,263
Written off during the financial year	(2,596)	-	-	-	(2,596)
At end of financial year	100,809	16,521	7,003	64,685	189,018
Accumulated depreciation					
At beginning of financial year	31,159	9,975	7,003	64,685	112,822
Depreciation for the financial year	30,141	4,695	-	-	34,836
At end of financial year	61,300	14,670	7,003	64,685	147,658
Net carrying amount					
At end of financial year	39,509	1,851	-	-	41,360
2020					
Cost		\$	\$	\$	\$
At beginning of financial year	-	16,195	7,003	64,685	87,883
Effect of adopting FRS116	44,142	-	-	-	44,142
At beginning of financial year restated	44,142	16,195	7,003	64,685	132,025
Additions during the financial year	-	326	-	-	326
At end of financial year	44,142	16,521	7,003	64,685	132,351
Accumulated depreciation					
At beginning of financial year	-	6,814	7,003	64,685	78,502
Depreciation for the financial year	31,159	3,161	-	-	34,320
At end of financial year	31,159	9,975	7,003	64,685	112,822
Net carrying amount					
At end of financial year	12,983	6,546	-	-	19,529

NOTES TO THE FINANCIAL STATEMENTS - 31 MARCH 2021

5. INVENTORIES

	2021	2020
	\$	\$
Finished goods	359,021	109,421

Finished goods comprised of medical and pharmaceutical products. The cost of inventories recognised as an expense and included cost of sale amount to \$607,500 (2020 \$235,927).

Included in finished goods is goods in transit amount to \$138,658 (2020:Nil)

6. CASH

	2021	2020
	\$	\$
Cash on hand	1,178	1,178
Cash at bank	226,601	56,704
	<u>227,779</u>	<u>57,882</u>

The carrying amounts of cash and cash equivalents approximate their fair values and are denominated in Singapore dollar.

7. TRADE AND OTHER RECEIVABLES

	2021	2020
	\$	\$
Trade receivables	791,489	237,038
Deposits	12,620	12,620
GST receivables	-	575
Other receivables	5,599	1,000
Amount due from director	33,142	66,668
Interest receivable	180,964	77,592
Loan to related party	2,039,100	2,041,896
	<u>3,062,914</u>	<u>2,437,389</u>

Loan to related company

Loan to related company is non-trade in nature and is repayable any time within 5 years. The interest charge is at 5% per annum.

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

7. TRADE AND OTHER RECEIVABLES (CONTINUED)

Amount due from director

These advance was made to the director to meet expenditure incurred or to be incurred by him for the purpose of enabling him to properly perform his duties as a director of the Company. These advances was approved at a general meeting of shareholders.

Trade receivables

Trade receivables are non-interest bearing and are generally on 30 to 90 days terms. They are recognised at their original invoice amounts which represent their fair values on initial recognition.

There are no trade receivables that are past due at the end of the reporting period. Trade receivables are all within its credit limit and management believes that no impairment allowance is necessary in respect of these balances as there had not been a significant change in credit quality and the balances were considered fully recoverable.

The carrying amounts of other receivables approximate their fair values and are denominated in the following currencies:

	2021	2020
	\$	\$
Singapore dollar	841,850	316,901
United States dollar	2,221,064	2,120,488
	<u>3,062,914</u>	<u>2,437,389</u>

8. TRADE AND OTHER PAYABLES

	2021	2020
	\$	\$
Trade payables - Holding company	199,538	170,953
Amount due to director	51,420	46,052
Interest payable	186,666	80,208
Other payable	15,400	15,400
Accrued expenses	12,622	-
GST payable	20,275	-
	<u>485,921</u>	<u>312,613</u>

Trade payables

Trade payables are non interest bearing and are normally settled on 30 days' term.

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

8. TRADE AND OTHER PAYABLES (CONTINUED)

Amount due to director

Amount due to director was non-trade related, unsecured, non-interest bearing and is repayable on demand.

The carrying amounts of trade and other payables approximate their fair values and are denominated in Singapore dollar.

9. INTEREST BEARING LOANS

	2021	2020
	\$	\$
Current		
Lease liability (Note 16)	40,163	13,325
Loan from holding company	2,100,000	2,100,000
	<u>2,140,163</u>	<u>2,113,325</u>

Movement in lease liability

Balance at beginning financial year	13,325	-
Adoption of FRS116	-	44,142
Addition during the year	59,264	-
Written off during the year	(2,688)	-
Accretion of interest	1,862	1,583
Lease payment	(31,600)	(32,400)
Balance at end financial year	<u>40,163</u>	<u>13,325</u>

Loan from holding company

Loan from holding company is unsecured and non-trade in nature and is repayable within 5 years. The interest rate charged on loan is 5% per annum.

The carrying amount of interest bearing loans approximate their fair values and are denominated in Singapore dollar.

10. SHARE CAPITAL

	2021	2021	2020	2020
	No. of shares	\$	No. of shares	\$
Issued and fully paid ordinary shares:				
At beginning of financial year	2,100,000	2,100,000	1,850,000	1,850,000
Shares issued during the financial year	-	-	250,000	250,000
At end of financial year	<u>2,100,000</u>	<u>2,100,000</u>	<u>2,100,000</u>	<u>2,100,000</u>

The holders of ordinary shares are entitled to receive dividends as and when declared by the Company. All ordinary shares carry one vote per share without restrictions and have no par value.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

11. OTHER INCOME

	2021	2020
	\$	\$
Government grant	20,600	2,255
Interest income	103,372	102,523
Gain on termination of lease	91	-
	<u>124,063</u>	<u>104,778</u>

12. FINANCE COSTS

	2021	2020
	\$	\$
Interest expense to related company	106,458	106,750
Interest on lease liabilities (Note 16(c))	1,862	1,583
	<u>108,320</u>	<u>108,333</u>

13. STAFF COST

	2021	2020
	\$	\$
Director's salary	146,576	149,082
Staff salaries and other related cost	56,472	107,276
CPF contributions	11,583	16,379
Director's accomodation	42,600	29,150
	<u>257,231</u>	<u>301,887</u>

14. PROFIT/(LOSS) BEFORE TAX

The following items have been included in arriving at profit/(loss) before tax:

	2021	2020
	\$	\$
<i>After charging:</i>		
Conference and exhibition	-	27,902
Professional fee	22,650	23,100
Product registration charges	30,100	24,487
	<u>30,100</u>	<u>24,487</u>

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

15. INCOME TAX EXPENSE

a) Income tax expense

	2021	2020
	\$	\$
Current year's income tax provision	-	-

b) Reconciliation of effective tax

	2021	2020
	\$	\$
Profit/(Loss) before tax	866,707	(252,642)
Income tax expense using the corporate tax rate of 17% (2020: 17%)	147,340	(42,949)
Non-deductible expenses	24,336	5,834
Income tax not subject to tax	(17,573)	-
Unutilised tax losses	-	37,115
Utilised tax losses	(154,103)	-
	-	-

c) Unutilised tax losses

	2021	2020
	\$	\$
Balance at beginning of financial year	1,515,490	1,262,848
Utilised in current year	(906,488)	-
Unutilised tax losses	-	252,642
Balance at end of financial year	609,002	1,515,490
Deferred tax benefit on above unrecorded	103,530	257,633
Tax rate	17%	17%

16. LEASES

Company as a lessee

The Company has lease contracts for building. The Company's obligations under these leases are secured by the lessor's title to the leased assets. The Company is restricted from assigning and subleasing the leased assets.

a) Carrying amounts of right-of-use assets classified within property, plant and equipment

	2021	2020
	\$	\$
Leasehold building		
Balance at beginning of financial year	12,983	44,142
Additional	59,263	-
Written off	(2,596)	-
Depreciation	(30,141)	(31,159)
Balance at end of financial year	<u>39,509</u>	<u>12,983</u>

b) Lease liabilities

The carrying amounts of lease liabilities (included under interest-bearing loans and borrowings) and the movements during the year are disclosed in Note 9 and the maturity analysis of lease liabilities is disclosed in Note 18 (b).

c) Amounts recognised in profit or loss

	2021	2020
	\$	\$
Depreciation of right-of-use assets	30,141	31,159
Interest expense on lease liabilities (Note 12)	1,862	1,583
Gain on termination of lease	(91)	-
Total amount recognised in profit or loss	<u>31,912</u>	<u>32,742</u>

d) Total cash outflow

The Company had total cash outflows for leases of \$31,691 (2020: \$33,983).

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

16. LEASES (CONTINUED)

e) Extension options

The Company lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Company's business needs. Management exercises significant judgement in determining whether these extension options are reasonably certain to be exercised (Note 3).

17. RELATED PARTY DISCLOSURE

During the financial year, in addition to information disclosed elsewhere in the financial statements, significant related party transactions between the Company and related parties carried out on terms agreed between the parties in the normal course of business are as follows:

a) Related Party

	2021	2020
	\$	\$
Professional fee paid to a company where a director has an interest	6,000	6,000
Interest income from related party	(103,372)	(102,523)
Interest expense to holding company	106,458	106,750
Purchases from holding company	857,100	267,445

b) Remuneration of key management personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including directors of the Company.

During the financial year, the following payments were made to the directors of the Company representing the total remuneration of key management personnel:

	2021	2020
	\$	\$
Directors' remuneration	146,576	149,082
Directors' accomodation	42,600	29,150

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

(a) Categories of financial instruments

The following tables set out the financial instruments as at the end of financial year:

	Assets at amortised cost \$	Liabilities at amortised cost \$	Total \$
2021			
<i>Assets</i>			
Cash	227,779	-	227,779
Trade and other receivables	3,062,914	-	3,062,914
	<u>3,290,693</u>	<u>-</u>	<u>3,290,693</u>
<i>Liabilities</i>			
Trade and other payables	-	453,024	453,024
Interest bearing loan	-	2,140,163	2,140,163
	<u>-</u>	<u>2,593,187</u>	<u>2,593,187</u>
2020			
<i>Assets</i>			
Cash	57,882	-	57,882
Trade and other receivables	2,436,814	-	2,436,814
	<u>2,494,696</u>	<u>-</u>	<u>2,494,696</u>
<i>Liabilities</i>			
Trade and other payables	-	312,613	312,613
Interest beating loan	-	2,113,325	2,113,325
	<u>-</u>	<u>2,425,938</u>	<u>2,425,938</u>

(b) Financial risk management objectives and policies

The Company's activities expose it to a variety of financial risks from its operation. The key financial risks include credit risk, liquidity risk and market risk (including foreign currency risk and interest rate risk).

18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (CONTINUED)

(b) *Financial risk management objectives and policies (continued)*

The Board of Directors reviews and agrees policies and procedures for the management of these risks, which are executed by the management team. It is, and has been throughout the current and previous financial year, the Company's policy that no trading in derivatives for speculative purposes shall be undertaken.

The following sections provide details regarding the Company's exposure to the above-mentioned financial risks and the objectives, policies and processes for the management of these risks.

There has been no change to the Company's exposure to these financial risks or the manner in which it manages and measures the risks.

Credit risk

Credit risk is the risk of loss that may arise on outstanding financial instruments should a counterparty default on its obligations. The Company's exposure to credit risk arises primarily from directors' accounts and other receivables.

The Company as adopted procedures in monitoring collections and default of payments from its debtors. In addition, trade receivable balance are monitored on an ongoing basis with the result that the Company's exposure to bad debts is not significant. Hence, the Company does not expect to incur material credit losses. Cash and cash equivalents are placed with reputable and regulated financial institutions. For other financial assets, the Company minimises credit risk by dealing mainly with high credit rating counterparties.

The Company has applied the simplified approach to providing for impairment for ECLs prescribed by FRS 109, which permits the use of the lifetime expected loss provision for impairment of trade receivables. To measure the ECLs, trade receivables have been grouped based on shared credit risk characteristics and the days past due. The ECLs also incorporated forward looking information.

Given (i) there was no significant default in prior year, the management considered the default of financial asset is minimal; and (ii) no adverse change in the business environment is anticipated, management considered that the expected credit loss rate of the debtors is minimal for all ageing bands. As a result, the ECL is determined to be insignificant.

All of the current portion of the trade and other receivable balances are expected to be recovered within one year.

Exposure to credit risk

At the end of the reporting period, the Company's maximum exposure to credit risk is represented by the carrying amount of each class of financial assets recognised in the balance sheet.

18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (CONTINUED)

(b) *Financial risk management objectives and policies (continued)*

Credit risk (continued)

Other receivables and loan to the related company

The Company assessed the latest performance and financial position of the counterparties, adjusted for the future outlook of the industry in which the counterparties operate in, and concluded that there has been no significant increase in the credit risk since the initial recognition of the financial assets. Accordingly, the Company measured the impairment loss allowance using 12-month ECL and determined that the ECL is insignificant.

Financial assets that are neither past due nor impaired

Trade and other receivables that are neither past due nor impaired are with creditworthy debtors with good payment records with the Company. Cash and cash equivalents are placed with or entered into with reputable financial institutions or companies with high credit ratings and no history of default.

Liquidity risk

Liquidity risk refers to the risk that the Company will encounter difficulties in meeting its short-term obligations due to shortage of funds. The Company's exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. It is managed by matching the payment and receipt cycles. The Company's objective is to maintain a balance between continuity of funding and flexibility through the use of stand-by credit facilities. The Company's operations are financed mainly through equity. The directors are satisfied that funds are available to finance the operations of the Company.

Analysis of financial instruments by remaining contractual maturities

The table below summarises the maturity profile of the Company's financial assets and liabilities at the reporting date based on contractual undiscounted repayment obligations.

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (CONTINUED)

(b) Financial risk management objectives and policies (continued)

Liquidity risk (continued)

	One year or less \$	Two to five years \$	Total \$
2021			
<u>Financial assets</u>			
Cash	227,779	-	227,779
Trade and other receivables	1,023,814	2,039,100	3,062,914
Total undiscounted financial assets	<u>1,251,593</u>	<u>2,039,100</u>	<u>3,290,693</u>
<u>Financial liabilities</u>			
Trade and other payables	453,024	-	453,024
Interest bearing loan	40,163	2,100,000	2,140,163
Total undiscounted financial liabilities	<u>493,187</u>	<u>2,100,000</u>	<u>2,593,187</u>
Total net undiscounted financial liabilities	<u>758,406</u>	<u>(60,900)</u>	<u>697,506</u>
	One year or less \$	Two to five years \$	Total \$
2020			
<u>Financial assets</u>			
Cash	57,882	-	57,882
Trade and other receivables	2,436,814	-	2,436,814
Total undiscounted financial assets	<u>2,494,696</u>	<u>-</u>	<u>2,494,696</u>
<u>Financial liabilities</u>			
Trade and other payables	312,613	-	312,613
Interest bearing loan	13,325	2,100,000	2,113,325
Total undiscounted financial liabilities	<u>325,938</u>	<u>2,100,000</u>	<u>2,425,938</u>
Total net undiscounted financial liabilities	<u>2,168,758</u>	<u>(2,100,000)</u>	<u>68,758</u>

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (CONTINUED)

(b) *Financial risk management objectives and policies (continued)*

Foreign currency risk

The Company's foreign exchange risk results mainly from cash flows from transactions denominated in foreign currencies. At present, the Company does not have any formal policy for hedging against currency risk. The Company ensures that the net exposure is kept to an acceptable level by buying or selling foreign currencies at spot rates, where necessary, to address short term imbalances.

The Company has transactional currency exposures arising from loans, sales or purchases that are denominated in a currency other than the functional currency of the Company, primarily USD.

The Company's currency exposures to the USD at the reporting date were as follows:

	2021	2020
	USD	USD
	S\$	S\$
<u>Financial assets</u>		
Trade and other receivables	2,221,064	2,120,488
Currency exposures	2,221,064	2,120,488

A 10% strengthening of Singapore dollar against the foreign currencies denominated balances as at the reporting date would decrease profit or loss by the amounts shown below. This analysis assumes that all other variables remain constant.

	Profit or loss (after tax)	
	2021	2020
	S\$	S\$
United States dollar	(184,348)	(176,001)

A 10% weakening of Singapore dollar against the above currencies would have had equal but opposite effect on the above currencies to the amounts shown above, on the basis that all other variables remain constant.

18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (CONTINUED)

(b) Financial risk management objectives and policies (continued)

Foreign currency risk (continued)

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Cash flow interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Fair value interest rate risk is the risk that the value of a financial instrument will fluctuate due to changes in market interest rates. As the Company has no interest-bearing assets, the Company's income and operating cash flows are substantially independent of changes in market interest rates.

19. FAIR VALUES

The fair value of a financial instrument is the amount at which the instrument could be exchanged or settled between knowledgeable and willing parties in an arm's length transaction.

The following methods and assumptions are used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value.

Cash and cash equivalents, other receivables and other payables

The carrying amounts of these balances approximate their fair values due to the short-term nature of these balances.

20. CAPITAL RISK MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern and to maintain an optimal capital structure so as to maximise shareholder value. In order to maintain or achieve an optimal capital structure, the Company may adjust the amount of dividend payment, return capital to shareholders, issue new shares, buy back issued shares, obtain new borrowings or sell assets to reduce borrowings.

The Company is not subject to externally imposed capital requirements. Management monitors capital based on a gearing ratio.

The gearing ratio is calculated as net debt divided by total capital. Net debt is calculated as other payables plus provision for directors' fees less cash and cash equivalents. Total capital is calculated as total equity plus net debt.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

NOTES TO THE FINANCIAL STATEMENTS – 31 MARCH 2021

20. CAPITAL RISK MANAGEMENT (CONTINUED)

	2021	2020
	\$	\$
Net debt	2,398,305	2,368,056
Total equity	1,064,990	198,283
Total capital	<u>3,463,295</u>	<u>2,566,339</u>
Gearing ratio	<u>69%</u>	<u>92%</u>

21. AUTHORISATION OF FINANCIAL STATEMENTS FOR ISSUE

The financial statements for the financial year ended 31 March 2021 were authorised for issue in accordance with a resolution of the Board of Directors of the Company on 28 April 2021.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

DETAILED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021

	2021	2020
	\$	\$
Revenue	1,889,454	500,272
Less : Purchases		
Purchases	857,100	267,446
Opening inventory	109,421	77,902
Less: Closing inventory	(359,021)	(109,421)
	<u>607,500</u>	<u>235,927</u>
Gross profit	1,281,954	264,345
Other Income		
Government Grant	20,600	2,255
Interest income	103,372	102,523
Gain on termination of lease	91	-
	<u>124,063</u>	<u>104,778</u>
	<u>1,406,017</u>	<u>369,123</u>
COSTS AND EXPENSES		
Staff Cost		
Staff salaries	54,600	104,720
Director's salary	146,576	149,082
CPF contribution	11,583	16,379
Skill Development Levy	137	195
Staff welfare	1,735	2,361
Rent - others	42,600	29,150
	<u>257,231</u>	<u>301,887</u>
Depreciation expense		
Depreciation - right use of asset	30,141	31,159
Depreciation - office equipment	4,695	3,161
	<u>34,836</u>	<u>34,320</u>
Finance cost		
Interest expense	108,320	108,333

This statement does not form part of the audited financial statements of the Company.

NATCO PHARMA ASIA PTE. LTD.
(Reg. No: 201230076Z)

DETAILED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2021 (CONTINUED)

	2021	2020
	\$	\$
Other Operating Expenses		
Audit fee	7,500	6,500
Bank charges	1,031	146
CDAC Expenses	28	37
Clearing expenses	4,628	8,624
Conference and Exhibition	-	27,902
Conveyance	25,695	18,448
Delivery charges	8,075	9,615
Electricity expenses - City Sq.	1,528	1,650
Electricity expenses - Ubi	1,451	1,613
Insurance charges	800	728
Office expenses	13,218	8,594
Printing and stationary expenses	1,235	4,739
Product registration charges (HSA)	30,100	24,487
Professional fees	22,650	23,100
Repair and maintainance	780	1,036
RLD sample purchase	-	26,910
Staff commission	12,968	1,315
Stamp and duty	445	-
Telephone expenses	6,791	7,574
Travelling expenses	-	4,206
	<u>138,923</u>	<u>177,224</u>
Profit/(Loss) representing total comprehensive income/(loss) for the financial year	<u>866,707</u>	<u>(252,642)</u>

This statement does not form part of the audited financial statements of the Company.